Pluri Inc. (PLUR) 10-Year Financial Performance & Capital Metrics

PLUR • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutPluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.Show more

Revenue $1M +309.8%
EBITDA -$22M +0.2%
Net Income -$23M -8.1%
EPS (Diluted) -3.56 +10.8%
Gross Margin 48.95% -50.4%
EBITDA Margin -1636.23% +75.6%
Operating Margin -1659.88% +75.6%
Net Margin -1690.34% +73.6%
ROE -992.66% -392.2%
ROIC -59.9% -22.7%
Debt/Equity -
Interest Coverage -25.40 +0.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 125.3%

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 9 (bottom 9%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y13.43%

5Y125.33%

3Y78.73%

TTM121.74%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-4.7%

EPS CAGR

10Y-

5Y-

3Y-

TTM20.58%

ROCE

10Y Avg-78.09%

5Y Avg-68.82%

3Y Avg-71.16%

Latest-107.06%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	2.85M	0	50K	54K	23K	0	234K	287K	326K	1.34M
Revenue Growth %	6.51%	-1%	-	0.08%	-0.57%	-1%	-	0.23%	0.14%	3.1%
Cost of Goods Sold+	100K	2.18M	2K	2K	1.57M	1.37M	1.05M	9K	4K	682K
COGS % of Revenue	0.04%	-	0.04%	0.04%	68.26%	-	4.5%	0.03%	0.01%	0.51%
Gross Profit+	2.75M	-2.18M	48K	52K	-1.55M	-1.37M	-819K	278K	322K	654K
Gross Margin %	0.96%	-	0.96%	0.96%	-67.26%	-	-3.5%	0.97%	0.99%	0.49%
Gross Profit Growth %	6.51%	-1.79%	1.02%	0.08%	-30.75%	0.11%	0.4%	1.34%	0.16%	1.03%
Operating Expenses+	26.07M	28.02M	33.78M	35.58M	27.93M	49.25M	40.77M	27.52M	22.48M	22.83M
OpEx % of Revenue	9.16%	-	675.58%	658.96%	1214.3%	-	174.25%	95.9%	68.96%	17.09%
Selling, General & Admin	6.49M	6.93M	11.19M	9.16M	7.8M	20.56M	17.45M	11.78M	10.03M	9.98M
SG&A % of Revenue	2.28%	-	223.86%	169.57%	339.35%	-	74.57%	41.04%	30.78%	7.47%
Research & Development	19.58M	21.09M	22.63M	24.59M	20.12M	30.07M	24.38M	15.74M	12.45M	12.85M
R&D % of Revenue	6.88%	-	452.58%	455.3%	874.96%	-	104.18%	54.86%	38.18%	9.62%
Other Operating Expenses	0	0	0	0	0	-1.37M	-1.05M	0	0	0
Operating Income+	-23.32M	-28.02M	-33.73M	-35.53M	-29.48M	-50.62M	-41.59M	-27.25M	-22.16M	-22.18M
Operating Margin %	-8.19%	-	-674.62%	-658%	-1281.57%	-	-177.75%	-94.93%	-67.97%	-16.6%
Operating Income Growth %	0.08%	-0.2%	-0.2%	-0.05%	0.17%	-0.72%	0.18%	0.34%	0.19%	-0%
EBITDA+	-21.17M	-25.84M	-31.71M	-33.57M	-27.91M	-49.25M	-40.54M	-26.88M	-21.91M	-21.86M
EBITDA Margin %	-7.44%	-	-634.26%	-621.67%	-1213.3%	-	-173.25%	-93.67%	-67.19%	-16.36%
EBITDA Growth %	0.09%	-0.22%	-0.23%	-0.06%	0.17%	-0.76%	0.18%	0.34%	0.19%	0%
D&A (Non-Cash Add-back)	2.15M	2.18M	2.02M	1.96M	1.57M	1.37M	1.05M	362K	253K	316K
EBIT	-23.32M	-27.75M	-26.13M	-35.31M	-28.96M	-49.79M	-40.49M	-28.04M	-20.48M	-22.38M
Net Interest Income+	49K	0	-661K	356K	188K	414K	-306K	241K	448K	271K
Interest Income	149K	122K	276K	385K	384K	492K	581K	1.08M	1.31M	1.14M
Interest Expense	100K	0	937K	29K	196K	78K	887K	843K	866K	873K
Other Income/Expense	73K	205K	7.61M	225K	324K	758K	219K	-1.64M	814K	-1.08M
Pretax Income+	-23.25M	-27.81M	-26.13M	-35.31M	-29.15M	-49.87M	-41.37M	-28.89M	-21.34M	-23.25M
Pretax Margin %	-8.17%	-	-522.52%	-653.83%	-1267.48%	-	-176.81%	-100.65%	-65.47%	-17.41%
Income Tax+	-73K	-205K	0	-94K	0	0	0	0	0	-5K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	0.98%	0.98%	0.97%
Net Income+	-23.25M	-27.81M	-26.13M	-35.31M	-29.15M	-49.87M	-41.24M	-28.32M	-20.89M	-22.58M
Net Margin %	-8.17%	-	-522.52%	-653.83%	-1267.48%	-	-176.25%	-98.68%	-64.07%	-16.9%
Net Income Growth %	0.06%	-0.2%	0.06%	-0.35%	0.17%	-0.71%	0.17%	0.31%	0.26%	-0.08%
Net Income (Continuing)	-23.25M	-27.81M	-26.13M	-35.31M	-29.15M	-49.87M	-41.37M	-28.89M	-21.34M	-23.25M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	2.15M	1.95M	5.32M	5.98M
EPS (Diluted)+	-23.38	-25.45	-19.74	-23.20	-12.80	-14.19	-10.24	-6.18	-3.99	-3.56
EPS Growth %	0.17%	-0.09%	0.22%	-0.18%	0.45%	-0.11%	0.28%	0.4%	0.35%	0.11%
EPS (Basic)	-23.38	-25.45	-19.74	-23.20	-12.80	-14.19	-10.24	-6.18	-3.99	-3.56
Diluted Shares Outstanding	994.35K	1.09M	1.32M	1.54M	2.27M	3.51M	4.02M	4.58M	5.24M	63.37M
Basic Shares Outstanding	994.35K	1.09M	1.32M	1.54M	2.27M	3.51M	4.02M	4.58M	5.24M	63.37M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	35.6M	29.02M	32.04M	26.37M	48.46M	67.37M	57.75M	41.41M	31.11M	22.09M
Cash & Short-Term Investments	32.21M	26.11M	29.9M	23.7M	46.34M	64.95M	55.02M	40.17M	29.98M	20.61M
Cash Only	6.22M	4.71M	8.82M	4.11M	8.82M	31.24M	9.77M	5.36M	6.78M	5.89M
Short-Term Investments	25.98M	21.4M	21.08M	19.6M	37.51M	33.71M	45.24M	34.81M	23.2M	14.72M
Accounts Receivable	2.48M	1.17M	847K	1.42M	1.61M	1.49M	1.32M	527K	638K	722K
Days Sales Outstanding	318.08	-	6.18K	9.6K	25.55K	-	2.06K	670.23	714.33	197.25
Inventory	0	0	0	692K	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	126.29K	-	-	-	-	-	-
Other Current Assets	607K	0	0	21K	67K	598K	1.01M	269K	262K	525K
Total Non-Current Assets+	10.35M	8.52M	6.92M	4.94M	17.07M	26.17M	10.32M	9.39M	8.42M	16.59M
Property, Plant & Equipment	9.22M	7.28M	5.68M	3.84M	3.77M	2.23M	9.01M	8.32M	7.25M	8.72M
Fixed Asset Turnover	0.31x	-	0.01x	0.01x	0.01x	-	0.03x	0.03x	0.04x	0.15x
Goodwill	0	0	0	0	0	0	0	0	0	3.14M
Intangible Assets	0	0	0	0	0	0	0	0	0	2.79M
Long-Term Investments	363K	403K	383K	398K	12.65M	0	0	0	0	0
Other Non-Current Assets	766K	838K	863K	703K	643K	23.94M	1.31M	1.07M	1.17M	1.94M
Total Assets+	45.94M	37.53M	38.96M	31.31M	65.53M	93.54M	68.06M	50.8M	39.53M	38.68M
Asset Turnover	0.06x	-	0.00x	0.00x	0.00x	-	0.00x	0.01x	0.01x	0.03x
Asset Growth %	-0.33%	-0.18%	0.04%	-0.2%	1.09%	0.43%	-0.27%	-0.25%	-0.22%	-0.02%
Total Current Liabilities+	5.78M	5.41M	8.55M	8.16M	7.99M	11.52M	6.83M	5.62M	4.45M	32.33M
Accounts Payable	2.71M	1.97M	3.26M	2.28M	1.97M	2.53M	1.78M	1.81M	964K	866K
Days Payables Outstanding	9.87K	329.62	595.13K	416.28K	457.53	672.99	618.73	73.49K	87.97K	463.48
Short-Term Debt	0	0	0	0	1.02M	0	0	0	0	27.29M
Deferred Revenue (Current)	0	0	640K	0	126K	40K	112K	151K	124K	341K
Other Current Liabilities	560K	687K	946K	0	3.02M	1.2M	1.51M	873K	702K	859K
Current Ratio	6.16x	5.36x	3.75x	3.23x	6.07x	5.85x	8.46x	7.37x	6.98x	0.68x
Quick Ratio	6.16x	5.36x	3.75x	3.15x	6.07x	5.85x	8.46x	7.37x	6.98x	0.68x
Cash Conversion Cycle	-	-	-	-280.39K	-	-	-	-	-	-
Total Non-Current Liabilities+	2.01M	1.87M	1.91M	1.33M	1.44M	24.87M	29.05M	29.88M	29.66M	7.22M
Long-Term Debt	0	0	0	0	0	23.85M	21.68M	23.53M	24.03M	0
Capital Lease Obligations	0	0	0	0	565K	100K	6.5M	5.75M	5.03M	6.1M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	415K
Other Non-Current Liabilities	2.01M	1.87M	1.91M	1.33M	879K	920K	867K	598K	605K	703K
Total Liabilities	7.79M	7.28M	10.45M	9.49M	9.43M	36.39M	35.88M	35.5M	34.11M	39.55M
Total Debt+	0	0	0	0	1.58M	24.58M	28.8M	29.91M	29.61M	34.05M
Net Debt	-6.22M	-4.71M	-8.82M	-4.11M	-7.24M	-6.66M	19.03M	24.55M	22.83M	28.16M
Debt / Equity	-	-	-	-	0.03x	0.43x	0.89x	1.95x	5.47x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-233.19x	-	-36.00x	-1225.24x	-150.39x	-649.01x	-46.89x	-32.32x	-25.59x	-25.40x
Total Equity+	38.16M	30.25M	28.51M	21.82M	56.1M	57.15M	32.19M	15.3M	5.42M	-865K
Equity Growth %	-0.34%	-0.21%	-0.06%	-0.23%	1.57%	0.02%	-0.44%	-0.52%	-0.65%	-1.16%
Book Value per Share	38.37	27.68	21.55	14.15	24.66	16.26	8.00	3.34	1.03	-0.01
Total Shareholders' Equity	38.16M	30.25M	28.51M	21.82M	56.1M	57.15M	30.04M	13.36M	96K	-6.84M
Common Stock	1K	1K	1K	1K	0	0	0	0	0	0
Retained Earnings	-161.76M	-189.57M	-215.7M	-251M	-280.16M	-330.02M	-371.26M	-399.58M	-420.47M	-443.06M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	1.48M	2M	-11.21M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	2.15M	1.95M	5.32M	5.98M

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	-18.52M	-21.61M	-21.38M	-29.45M	-26.37M	-30.91M	-36.5M	-22.86M	-18.02M	-18.21M
Operating CF Margin %	-6.51%	-	-427.6%	-545.43%	-1146.48%	-	-155.99%	-79.64%	-55.28%	-13.63%
Operating CF Growth %	0.1%	-0.17%	0.01%	-0.38%	0.1%	-0.17%	-0.18%	0.37%	0.21%	-0.01%
Net Income	-23.25M	-27.81M	-26.13M	-35.31M	-29.15M	-49.87M	-41.37M	-28.89M	-21.34M	-23.25M
Depreciation & Amortization	2.15M	2.18M	2.02M	1.96M	1.57M	1.37M	1.05M	362K	253K	316K
Stock-Based Compensation	3.07M	3.66M	6.55M	5.15M	2.56M	13.97M	8.91M	3.98M	2.62M	2.14M
Deferred Taxes	425K	512K	-7.57M	0	0	0	-15.18M	-5.32M	0	0
Other Non-Cash Items	-3K	-14K	5K	-3K	-11K	86K	15.18M	5.32M	473K	-1.61M
Working Capital Changes	-921K	-134K	3.75M	-1.25M	-1.34M	3.53M	-5.09M	1.69M	-21K	4.19M
Change in Receivables	-537K	1.19M	978K	-121K	37K	-256K	-329K	-336K	438K	-111K
Change in Inventory	2.63M	-24.23M	-21.93M	0	-789K	0	329K	336K	0	0
Change in Payables	-77K	-701K	1.21M	-863K	-291K	578K	-758K	-22K	-778K	-235K
Cash from Investing+	1.31M	4.3M	5.57M	1.17M	-30.46M	-7.26M	11.78M	9.7M	10.58M	8.03M
Capital Expenditures	-1.75M	-378K	-342K	-239K	-270K	-373K	-280K	-262K	-323K	-1.62M
CapEx % of Revenue	0.61%	-	6.84%	4.43%	11.74%	-	1.2%	0.91%	0.99%	1.21%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	5K	30K	1.94M	-6K	-12.24M	0	0	0	0	0
Cash from Financing+	807K	15.8M	19.92M	23.58M	60.87M	61.4M	7.5M	8.02M	8.84M	9.53M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	17K	79K	1.29M	115K	2.71M	364K	9.67M	0	8.75M	-47K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-20.27M	-21.99M	-21.72M	-29.69M	-26.64M	-31.28M	-36.78M	-23.12M	-18.34M	-19.83M
FCF Margin %	-7.12%	-	-434.44%	-549.85%	-1158.22%	-	-157.18%	-80.55%	-56.27%	-14.84%
FCF Growth %	0.05%	-0.08%	0.01%	-0.37%	0.1%	-0.17%	-0.18%	0.37%	0.21%	-0.08%
FCF per Share	-20.39	-20.12	-16.42	-19.26	-11.71	-8.90	-9.14	-5.05	-3.50	-0.31
FCF Conversion (FCF/Net Income)	0.80x	0.78x	0.82x	0.83x	0.90x	0.62x	0.89x	0.81x	0.86x	0.81x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	66K	-28K	-27K	-10K	-10K	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-48.28%	-81.32%	-88.93%	-140.31%	-74.82%	-88.06%	-92.33%	-119.28%	-201.67%	-992.66%
Return on Invested Capital (ROIC)	-51.86%	-73.12%	-111.86%	-142.5%	-66.41%	-76.43%	-61.34%	-44.88%	-48.81%	-59.9%
Gross Margin	96.49%	-	96%	96.3%	-6726.09%	-	-350%	96.86%	98.77%	48.95%
Net Margin	-816.51%	-	-52252%	-65383.33%	-126747.83%	-	-17624.79%	-9867.94%	-6407.36%	-1690.34%
Debt / Equity	-	-	-	-	0.03x	0.43x	0.89x	1.95x	5.47x	-
Interest Coverage	-233.19x	-	-36.00x	-1225.24x	-150.39x	-649.01x	-46.89x	-32.32x	-25.59x	-25.40x
FCF Conversion	0.80x	0.78x	0.82x	0.83x	0.90x	0.62x	0.89x	0.81x	0.86x	0.81x
Revenue Growth	651.19%	-100%	-	8%	-57.41%	-100%	-	22.65%	13.59%	309.82%

Frequently Asked Questions

Growth & Financials

Pluri Inc. (PLUR) reported $1.3M in revenue for fiscal year 2025. This represents a 85% increase from $0.7M in 2012.

Pluri Inc. (PLUR) grew revenue by 309.8% over the past year. This is strong growth.

Pluri Inc. (PLUR) reported a net loss of $22.8M for fiscal year 2025.

Dividend & Returns

Pluri Inc. (PLUR) has a return on equity (ROE) of -992.7%. Negative ROE indicates the company is unprofitable.

Pluri Inc. (PLUR) had negative free cash flow of $21.1M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

Pluri Inc. (PLUR) 10-Year Financial Performance & Capital Metrics

PLUR • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

Revenue $1M +309.8%
EBITDA -$22M +0.2%
Net Income -$23M -8.1%
EPS (Diluted) -3.56 +10.8%
Gross Margin 48.95% -50.4%
EBITDA Margin -1636.23% +75.6%
Operating Margin -1659.88% +75.6%
Net Margin -1690.34% +73.6%
ROE -992.66% -392.2%
ROIC -59.9% -22.7%
Debt/Equity -
Interest Coverage -25.40 +0.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 125.3%

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 9 (bottom 9%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y13.43%

5Y125.33%

3Y78.73%

TTM121.74%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-4.7%

EPS CAGR

10Y-

5Y-

3Y-

TTM20.58%

ROCE

10Y Avg-78.09%

5Y Avg-68.82%

3Y Avg-71.16%

Latest-107.06%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	2.85M	0	50K	54K	23K	0	234K	287K	326K	1.34M
Revenue Growth %	6.51%	-1%	-	0.08%	-0.57%	-1%	-	0.23%	0.14%	3.1%
Cost of Goods Sold+	100K	2.18M	2K	2K	1.57M	1.37M	1.05M	9K	4K	682K
COGS % of Revenue	0.04%	-	0.04%	0.04%	68.26%	-	4.5%	0.03%	0.01%	0.51%
Gross Profit+	2.75M	-2.18M	48K	52K	-1.55M	-1.37M	-819K	278K	322K	654K
Gross Margin %	0.96%	-	0.96%	0.96%	-67.26%	-	-3.5%	0.97%	0.99%	0.49%
Gross Profit Growth %	6.51%	-1.79%	1.02%	0.08%	-30.75%	0.11%	0.4%	1.34%	0.16%	1.03%
Operating Expenses+	26.07M	28.02M	33.78M	35.58M	27.93M	49.25M	40.77M	27.52M	22.48M	22.83M
OpEx % of Revenue	9.16%	-	675.58%	658.96%	1214.3%	-	174.25%	95.9%	68.96%	17.09%
Selling, General & Admin	6.49M	6.93M	11.19M	9.16M	7.8M	20.56M	17.45M	11.78M	10.03M	9.98M
SG&A % of Revenue	2.28%	-	223.86%	169.57%	339.35%	-	74.57%	41.04%	30.78%	7.47%
Research & Development	19.58M	21.09M	22.63M	24.59M	20.12M	30.07M	24.38M	15.74M	12.45M	12.85M
R&D % of Revenue	6.88%	-	452.58%	455.3%	874.96%	-	104.18%	54.86%	38.18%	9.62%
Other Operating Expenses	0	0	0	0	0	-1.37M	-1.05M	0	0	0
Operating Income+	-23.32M	-28.02M	-33.73M	-35.53M	-29.48M	-50.62M	-41.59M	-27.25M	-22.16M	-22.18M
Operating Margin %	-8.19%	-	-674.62%	-658%	-1281.57%	-	-177.75%	-94.93%	-67.97%	-16.6%
Operating Income Growth %	0.08%	-0.2%	-0.2%	-0.05%	0.17%	-0.72%	0.18%	0.34%	0.19%	-0%
EBITDA+	-21.17M	-25.84M	-31.71M	-33.57M	-27.91M	-49.25M	-40.54M	-26.88M	-21.91M	-21.86M
EBITDA Margin %	-7.44%	-	-634.26%	-621.67%	-1213.3%	-	-173.25%	-93.67%	-67.19%	-16.36%
EBITDA Growth %	0.09%	-0.22%	-0.23%	-0.06%	0.17%	-0.76%	0.18%	0.34%	0.19%	0%
D&A (Non-Cash Add-back)	2.15M	2.18M	2.02M	1.96M	1.57M	1.37M	1.05M	362K	253K	316K
EBIT	-23.32M	-27.75M	-26.13M	-35.31M	-28.96M	-49.79M	-40.49M	-28.04M	-20.48M	-22.38M
Net Interest Income+	49K	0	-661K	356K	188K	414K	-306K	241K	448K	271K
Interest Income	149K	122K	276K	385K	384K	492K	581K	1.08M	1.31M	1.14M
Interest Expense	100K	0	937K	29K	196K	78K	887K	843K	866K	873K
Other Income/Expense	73K	205K	7.61M	225K	324K	758K	219K	-1.64M	814K	-1.08M
Pretax Income+	-23.25M	-27.81M	-26.13M	-35.31M	-29.15M	-49.87M	-41.37M	-28.89M	-21.34M	-23.25M
Pretax Margin %	-8.17%	-	-522.52%	-653.83%	-1267.48%	-	-176.81%	-100.65%	-65.47%	-17.41%
Income Tax+	-73K	-205K	0	-94K	0	0	0	0	0	-5K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	0.98%	0.98%	0.97%
Net Income+	-23.25M	-27.81M	-26.13M	-35.31M	-29.15M	-49.87M	-41.24M	-28.32M	-20.89M	-22.58M
Net Margin %	-8.17%	-	-522.52%	-653.83%	-1267.48%	-	-176.25%	-98.68%	-64.07%	-16.9%
Net Income Growth %	0.06%	-0.2%	0.06%	-0.35%	0.17%	-0.71%	0.17%	0.31%	0.26%	-0.08%
Net Income (Continuing)	-23.25M	-27.81M	-26.13M	-35.31M	-29.15M	-49.87M	-41.37M	-28.89M	-21.34M	-23.25M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	2.15M	1.95M	5.32M	5.98M
EPS (Diluted)+	-23.38	-25.45	-19.74	-23.20	-12.80	-14.19	-10.24	-6.18	-3.99	-3.56
EPS Growth %	0.17%	-0.09%	0.22%	-0.18%	0.45%	-0.11%	0.28%	0.4%	0.35%	0.11%
EPS (Basic)	-23.38	-25.45	-19.74	-23.20	-12.80	-14.19	-10.24	-6.18	-3.99	-3.56
Diluted Shares Outstanding	994.35K	1.09M	1.32M	1.54M	2.27M	3.51M	4.02M	4.58M	5.24M	63.37M
Basic Shares Outstanding	994.35K	1.09M	1.32M	1.54M	2.27M	3.51M	4.02M	4.58M	5.24M	63.37M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	35.6M	29.02M	32.04M	26.37M	48.46M	67.37M	57.75M	41.41M	31.11M	22.09M
Cash & Short-Term Investments	32.21M	26.11M	29.9M	23.7M	46.34M	64.95M	55.02M	40.17M	29.98M	20.61M
Cash Only	6.22M	4.71M	8.82M	4.11M	8.82M	31.24M	9.77M	5.36M	6.78M	5.89M
Short-Term Investments	25.98M	21.4M	21.08M	19.6M	37.51M	33.71M	45.24M	34.81M	23.2M	14.72M
Accounts Receivable	2.48M	1.17M	847K	1.42M	1.61M	1.49M	1.32M	527K	638K	722K
Days Sales Outstanding	318.08	-	6.18K	9.6K	25.55K	-	2.06K	670.23	714.33	197.25
Inventory	0	0	0	692K	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	126.29K	-	-	-	-	-	-
Other Current Assets	607K	0	0	21K	67K	598K	1.01M	269K	262K	525K
Total Non-Current Assets+	10.35M	8.52M	6.92M	4.94M	17.07M	26.17M	10.32M	9.39M	8.42M	16.59M
Property, Plant & Equipment	9.22M	7.28M	5.68M	3.84M	3.77M	2.23M	9.01M	8.32M	7.25M	8.72M
Fixed Asset Turnover	0.31x	-	0.01x	0.01x	0.01x	-	0.03x	0.03x	0.04x	0.15x
Goodwill	0	0	0	0	0	0	0	0	0	3.14M
Intangible Assets	0	0	0	0	0	0	0	0	0	2.79M
Long-Term Investments	363K	403K	383K	398K	12.65M	0	0	0	0	0
Other Non-Current Assets	766K	838K	863K	703K	643K	23.94M	1.31M	1.07M	1.17M	1.94M
Total Assets+	45.94M	37.53M	38.96M	31.31M	65.53M	93.54M	68.06M	50.8M	39.53M	38.68M
Asset Turnover	0.06x	-	0.00x	0.00x	0.00x	-	0.00x	0.01x	0.01x	0.03x
Asset Growth %	-0.33%	-0.18%	0.04%	-0.2%	1.09%	0.43%	-0.27%	-0.25%	-0.22%	-0.02%
Total Current Liabilities+	5.78M	5.41M	8.55M	8.16M	7.99M	11.52M	6.83M	5.62M	4.45M	32.33M
Accounts Payable	2.71M	1.97M	3.26M	2.28M	1.97M	2.53M	1.78M	1.81M	964K	866K
Days Payables Outstanding	9.87K	329.62	595.13K	416.28K	457.53	672.99	618.73	73.49K	87.97K	463.48
Short-Term Debt	0	0	0	0	1.02M	0	0	0	0	27.29M
Deferred Revenue (Current)	0	0	640K	0	126K	40K	112K	151K	124K	341K
Other Current Liabilities	560K	687K	946K	0	3.02M	1.2M	1.51M	873K	702K	859K
Current Ratio	6.16x	5.36x	3.75x	3.23x	6.07x	5.85x	8.46x	7.37x	6.98x	0.68x
Quick Ratio	6.16x	5.36x	3.75x	3.15x	6.07x	5.85x	8.46x	7.37x	6.98x	0.68x
Cash Conversion Cycle	-	-	-	-280.39K	-	-	-	-	-	-
Total Non-Current Liabilities+	2.01M	1.87M	1.91M	1.33M	1.44M	24.87M	29.05M	29.88M	29.66M	7.22M
Long-Term Debt	0	0	0	0	0	23.85M	21.68M	23.53M	24.03M	0
Capital Lease Obligations	0	0	0	0	565K	100K	6.5M	5.75M	5.03M	6.1M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	415K
Other Non-Current Liabilities	2.01M	1.87M	1.91M	1.33M	879K	920K	867K	598K	605K	703K
Total Liabilities	7.79M	7.28M	10.45M	9.49M	9.43M	36.39M	35.88M	35.5M	34.11M	39.55M
Total Debt+	0	0	0	0	1.58M	24.58M	28.8M	29.91M	29.61M	34.05M
Net Debt	-6.22M	-4.71M	-8.82M	-4.11M	-7.24M	-6.66M	19.03M	24.55M	22.83M	28.16M
Debt / Equity	-	-	-	-	0.03x	0.43x	0.89x	1.95x	5.47x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-233.19x	-	-36.00x	-1225.24x	-150.39x	-649.01x	-46.89x	-32.32x	-25.59x	-25.40x
Total Equity+	38.16M	30.25M	28.51M	21.82M	56.1M	57.15M	32.19M	15.3M	5.42M	-865K
Equity Growth %	-0.34%	-0.21%	-0.06%	-0.23%	1.57%	0.02%	-0.44%	-0.52%	-0.65%	-1.16%
Book Value per Share	38.37	27.68	21.55	14.15	24.66	16.26	8.00	3.34	1.03	-0.01
Total Shareholders' Equity	38.16M	30.25M	28.51M	21.82M	56.1M	57.15M	30.04M	13.36M	96K	-6.84M
Common Stock	1K	1K	1K	1K	0	0	0	0	0	0
Retained Earnings	-161.76M	-189.57M	-215.7M	-251M	-280.16M	-330.02M	-371.26M	-399.58M	-420.47M	-443.06M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	1.48M	2M	-11.21M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	2.15M	1.95M	5.32M	5.98M

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	-18.52M	-21.61M	-21.38M	-29.45M	-26.37M	-30.91M	-36.5M	-22.86M	-18.02M	-18.21M
Operating CF Margin %	-6.51%	-	-427.6%	-545.43%	-1146.48%	-	-155.99%	-79.64%	-55.28%	-13.63%
Operating CF Growth %	0.1%	-0.17%	0.01%	-0.38%	0.1%	-0.17%	-0.18%	0.37%	0.21%	-0.01%
Net Income	-23.25M	-27.81M	-26.13M	-35.31M	-29.15M	-49.87M	-41.37M	-28.89M	-21.34M	-23.25M
Depreciation & Amortization	2.15M	2.18M	2.02M	1.96M	1.57M	1.37M	1.05M	362K	253K	316K
Stock-Based Compensation	3.07M	3.66M	6.55M	5.15M	2.56M	13.97M	8.91M	3.98M	2.62M	2.14M
Deferred Taxes	425K	512K	-7.57M	0	0	0	-15.18M	-5.32M	0	0
Other Non-Cash Items	-3K	-14K	5K	-3K	-11K	86K	15.18M	5.32M	473K	-1.61M
Working Capital Changes	-921K	-134K	3.75M	-1.25M	-1.34M	3.53M	-5.09M	1.69M	-21K	4.19M
Change in Receivables	-537K	1.19M	978K	-121K	37K	-256K	-329K	-336K	438K	-111K
Change in Inventory	2.63M	-24.23M	-21.93M	0	-789K	0	329K	336K	0	0
Change in Payables	-77K	-701K	1.21M	-863K	-291K	578K	-758K	-22K	-778K	-235K
Cash from Investing+	1.31M	4.3M	5.57M	1.17M	-30.46M	-7.26M	11.78M	9.7M	10.58M	8.03M
Capital Expenditures	-1.75M	-378K	-342K	-239K	-270K	-373K	-280K	-262K	-323K	-1.62M
CapEx % of Revenue	0.61%	-	6.84%	4.43%	11.74%	-	1.2%	0.91%	0.99%	1.21%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	5K	30K	1.94M	-6K	-12.24M	0	0	0	0	0
Cash from Financing+	807K	15.8M	19.92M	23.58M	60.87M	61.4M	7.5M	8.02M	8.84M	9.53M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	17K	79K	1.29M	115K	2.71M	364K	9.67M	0	8.75M	-47K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-20.27M	-21.99M	-21.72M	-29.69M	-26.64M	-31.28M	-36.78M	-23.12M	-18.34M	-19.83M
FCF Margin %	-7.12%	-	-434.44%	-549.85%	-1158.22%	-	-157.18%	-80.55%	-56.27%	-14.84%
FCF Growth %	0.05%	-0.08%	0.01%	-0.37%	0.1%	-0.17%	-0.18%	0.37%	0.21%	-0.08%
FCF per Share	-20.39	-20.12	-16.42	-19.26	-11.71	-8.90	-9.14	-5.05	-3.50	-0.31
FCF Conversion (FCF/Net Income)	0.80x	0.78x	0.82x	0.83x	0.90x	0.62x	0.89x	0.81x	0.86x	0.81x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	66K	-28K	-27K	-10K	-10K	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-48.28%	-81.32%	-88.93%	-140.31%	-74.82%	-88.06%	-92.33%	-119.28%	-201.67%	-992.66%
Return on Invested Capital (ROIC)	-51.86%	-73.12%	-111.86%	-142.5%	-66.41%	-76.43%	-61.34%	-44.88%	-48.81%	-59.9%
Gross Margin	96.49%	-	96%	96.3%	-6726.09%	-	-350%	96.86%	98.77%	48.95%
Net Margin	-816.51%	-	-52252%	-65383.33%	-126747.83%	-	-17624.79%	-9867.94%	-6407.36%	-1690.34%
Debt / Equity	-	-	-	-	0.03x	0.43x	0.89x	1.95x	5.47x	-
Interest Coverage	-233.19x	-	-36.00x	-1225.24x	-150.39x	-649.01x	-46.89x	-32.32x	-25.59x	-25.40x
FCF Conversion	0.80x	0.78x	0.82x	0.83x	0.90x	0.62x	0.89x	0.81x	0.86x	0.81x
Revenue Growth	651.19%	-100%	-	8%	-57.41%	-100%	-	22.65%	13.59%	309.82%

Frequently Asked Questions

Growth & Financials

Pluri Inc. (PLUR) reported $1.3M in revenue for fiscal year 2025. This represents a 85% increase from $0.7M in 2012.

Pluri Inc. (PLUR) grew revenue by 309.8% over the past year. This is strong growth.

Pluri Inc. (PLUR) reported a net loss of $22.8M for fiscal year 2025.

Dividend & Returns

Pluri Inc. (PLUR) has a return on equity (ROE) of -992.7%. Negative ROE indicates the company is unprofitable.

Pluri Inc. (PLUR) had negative free cash flow of $21.1M in fiscal year 2025, likely due to heavy capital investments.